Stock index futures are pointing slightly higher following yesterday’s rally. Investors continue to assess the potential impacts of President Trump’s tariff plans, which have introduced uncertainty regarding future trade relations.
In the commodities market, gold prices have edged higher amid ongoing tariff uncertainties and their potential effects on the global economy. Spot gold rose 0.3% to $3,020.73 an ounce, reflecting investors’ inclination toward safe-haven assets during periods of economic ambiguity. Oil prices have experienced a slight uptick, marking the fifth consecutive day of gains, which is being attributed to U.S. tariffs on Venezuelan crude buyers. Brent crude futures are trading at $71.91 per barrel, while U.S. West Texas Intermediate crude stands at $68.08 per barrel.
Investors are also closely monitoring upcoming economic indicators, including the U.S. Federal Reserve’s preferred inflation report, the Personal Consumption Expenditure index, due later this week.
In pre-market trading, S&P 500 futures rose 0.24%, Nasdaq futures rose 0.23% and Dow futures rose 0.17%.
Check out this morning’s top movers from around Wall Street, compiled by The Fly.
HIGHER –
- Mobileye (MBLY) up 15% after Volkswagen (VWAGY) announced it is working with Valeo and the company to upgrade the advanced driver assistance systems up to Level 2+ in its upcoming vehicle portfolio based on the MQB platform
- Faraday Future (FFAI) up 10% after securing $41M in new cash financing commitments
- Trump Media (DJT) up 8% after announcing it has signed a non-binding agreement to partner with Crypto.com to launch a series of exchange-traded funds and exchange-traded products through the Truth.Fi brand
UP AFTER EARNINGS –
DOWN AFTER EARNINGS –
- CorMedix (CRMD) down 17%
- Viomi Technology (VIOT) down 8%
- Core & Main (CNM) down 3%
- McCormick (MKC) down 1%
LOWER –
- CNS Pharmaceuticals (CNSP) down 60% after the company reported that the primary analysis of its clinical trial evaluating Berubicin for the treatment of recurrent or progressive Glioblastoma Multiforme did not demonstrate statistically significant superiority in overall survival, the primary endpoint
- Cassava Sciences (SAVA) down 20% after announcing its REFOCUS-ALZ trial did not meet each of the prespecified co-primary, secondary and exploratory biomarker endpoints
- UniFirst (UNF) down 10% after Cintas (CTAS) announced that it has terminated discussions with the company regarding Cintas’ proposal to acquire all of the outstanding common and class B shares of UniFirst for $275.00 per share in cash